Author(s) :
Bianca Homorozeanu1,2, Miruna Zaha3, Daniel Sur1,2, Zsolt Fekete1,2
1 Department of Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
2 Institute of Oncology “Prof Dr. Ion Chiricuță“, Cluj-Napoca, Romania
3 „Iuliu Hațieganu University of Medicine and Pharmacy”, Cluj-Napoca, Romania
Corresponding author: Zaha Miruna, Email: zaha_miruna@yahoo.com
Publication History: Received - , Revised - , Accepted - , Published Online - 29 July 2024.
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Valoarea DOI extrasă din ACF este: 10.53011/JMRO.2024.01.09
Număr de citări pe Crossref pentru DOI 10.53011/JMRO.2024.01.09: 0
Verifică manual răspunsul API la acest link: http://api.crossref.org/works/10.53011/JMRO.2024.01.09
Abstract
Gliomas account for the great majority of primary tumors that arise within the central nervous system (CNS). The term “glioma” refers to tumors that have histologic features similar to normal glial cells (ie, astrocytes, oligodendrocytes, and ependymal cells). Each of these types of gliomas contains neoplasms spanning a broad spectrum of biologic aggressiveness.
We present the case of a 47 year old male, with the diagnosis of frontal grade III anaplastic oligoastrocytoma in 2007, who undergoes surgery and who presents a local recurrence after 4 years. After the second surgical intervention with complete removal of the tumor, the histopathological examination reveals the diagnosis of grade III oligoastrocytoma. Postoperatively, the patient undergoes 2 cycles of chemotherapy with Temozolomide and considering the histology, age and the patient’s comorbidities, he completes the treatment with concurrent radiochemotherapy, followed by adjuvant chemotherapy. In 2023 he has a second relapse for which he undergoes surgery. Histopathological report shows that the tumor has transformed into a grade IV astrocytoma. Following surgery, concurrent radio-chemotherapy is instituted for 6 weeks. After the completion of the radio-chemotherapy, he undergoes chemotherapy and follow-up through brain MRI.
